Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005/03/01 by H. Shigematsu, Hisayuki Shigematsu, Lin Li +28 · 2,407 citations
Medicine · #Adenocarcinoma #Biology #Cancer #Cancer research #Colorectal cancer #Epidermal growth factor #Epidermal growth factor receptor #Exon #Gene #Gene mutation #Genetics #Internal medicine #KRAS #Lung #Lung Cancer Diagnosis and Treatment #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations #Lung cancer #Medicine #Mutation #Oncology #Pathology #Receptor #Tyrosine kinase
paper · doi:10.1093/jnci/dji055
published in JNCI Journal of the National Cancer Institute 97(5), 339-346 (Oxford University Press)
openalex publication_date 2005/03/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Abstract
BACKGROUND: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity. However, the role of such mutations in the pathogenesis of lung cancers is unclear. METHODS: We sequenced exons 18-21 of the EGFR TK domain from genomic DNA isolated from 617 non-small-cell lung cancers (NSCLCs) and 524 normal lung tissue samples from the same patients and 36 neuroendocrine lung tumors collected from patients in Japan, Taiwan, the United States, and Australia and from 243 other epithelial cancers. Mutation status was compared with clinicopathologic features and with the presence of mutations in KRAS, a gene in the EGFR signaling pathway that is also frequently mutated in lung cancers. All statistical tests were two sided. RESULTS: We detected a total of 134 EGFR TK domain mutations in 130 (21%) of the 617 NSCLCs but not in any of the other carcinomas, nor in nonmalignant lung tissue from the same patients. In NSCLC patients, EGFR TK domain mutations were statistically significantly more frequent in never smokers than ever smokers (51% versus 10%), in adenocarcinomas versus cancer of other histologies (40% versus 3%), in patients of East Asian ethnicity versus other ethnicities (30% versus 8%), and in females versus males (42% versus 14%; all P < .001). EGFR TK domain mutation status was not associated with patient age at diagnosis, clinical stage, the presence of bronchioloalveolar histologic features, or overall survival. The EGFR TK domain mutations we detected were of three common types: in-frame deletions in exon 19, single missense mutations in exon 21, and in-frame duplications/insertions in exon 20. Rare missense mutations were also detected in exons 18, 20, and 21. KRAS gene mutations were present in 50 (8%) of the 617 NSCLCs but not in any tumors with an EGFR TK domain mutation. CONCLUSIONS: Mutations in either the EGFR TK domain or the KRAS gene can lead to lung cancer pathogenesis. EGFR TK domain mutations are the first molecular change known to occur specifically in never smokers.
Cited by
- Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications
- Disparities in cancer genomics by ancestry in the 100,000 Genomes Project
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- Highly sensitive EGFR mutation detection by specific amplification of mutant alleles
- BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. [europepmc]
- PIK3CA mutations and copy number gains in human lung cancers. [europepmc]
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. [europepmc]
- The biology and treatment of EML4-ALK non-small cell lung cancer. [europepmc]
- Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. [europepmc]
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. [europepmc]
- International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. [europepmc]
- Lung cancer: epidemiology, etiology, and prevention. [europepmc]
- Targeting the EGFR signaling pathway in cancer therapy. [europepmc]
- Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. [europepmc]
- Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. [europepmc]
- EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. [europepmc]
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. [europepmc]
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). [europepmc]
- ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. [europepmc]
- Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. [europepmc]
- A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). [europepmc]
- Fragment Length of Circulating Tumor DNA. [europepmc]
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. [europepmc]
- Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. [europepmc]
- Kinase-targeted cancer therapies: progress, challenges and future directions. [europepmc]
- The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. [europepmc]
- Cancer health disparities in racial/ethnic minorities in the United States. [europepmc]
- Kinase drug discovery 20 years after imatinib: progress and future directions. [europepmc]
- Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. [europepmc]
Related